Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories, heterogeneous patient populations, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations. Traditional scales such as ADAS-Cog and MDS-UPDRS, while well-established, often lack sensitivity in early disease, are vulnerable to rater and practice effects, and may insufficiently capture subtle...
